The Neo-PLANET phase II trial of neoadjuvant camrelizumab plus concurrent chemoradiotherapy in locally advanced adenocarcinoma of stomach or gastroesophageal junction

Zhaoqing Tang(Fudan University), Yihong Sun(South China Agricultural University)
Nature Communications
November 10, 2022
10.1038/s41467-022-34403-5
Cited by 82

Related Papers

Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial
|The Lancet Oncology|2021|436
Decreased expression of STING predicts poor prognosis in patients with gastric cancer
|Scientific Reports|2017|224
NOTCH3 is a Prognostic Factor and Is Correlated With Immune Tolerance in Gastric Cancer
|Frontiers in Oncology|2021|79
High expression of CD39 in gastric cancer reduces patient outcome following radical resection
|Oncology Letters|2016|57